• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

WaveForm touts clinical trial data for continuous glucose monitor

January 16, 2018 By Sarah Faulkner

WaveFormWaveForm Technologies said today that it has finished four clinical trials of its continuous glucose monitoring system and that it expects to win CE Mark clearance for the device this year.

The WaveForm CGM system is designed to be worn for 14 days and includes a sensor insertion tool, a small sensor wire, a polymer coating and an on-body transmitter.

The company, which was formed after AgaMatrix split last year, noted that its CGM will connect directly with a patient’s smartphone using Bluetooth, eliminating the need for an extra receiver.

WaveForm’s CGM boasts several advantages compared to currently-available products, the company suggested, including fast and painless on-body sensor insertion and the ability to take one glucose measurement every minute. The system also needs just one calibration each day and features longer wear-time than traditional devices.

In one study conducted last year, 10 patients wore a WaveForm CGM and one of Dexcom‘s (NSDQ:DXCM) G5 Platinum Sensor CGM at the same time for seven days. The WaveForm device had a mean absolute relative deviation of 11.1%, compared to 12.2% for Dexcom’s product.

“We believe these clinical trial results support the safety, efficacy and potential of WaveForm’s CGM technology, and the commencement of pivotal studies designed to secure commercial approval,” chief technical officer Mihailo Rebec said in prepared remarks.

“We look forward to commencing additional studies using our improved sensor algorithm in early 2018, which we expect will indicate continued improvements in system accuracy, and to completing pivotal studies that will serve as the basis for seeking approval to market the WaveForm CGM in the European Union.”

The company is also planning to begin development for a closed-loop insulin delivery system integrated with its CGM this year.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development Tagged With: DexCom Inc., waveformtechnologies

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS